OAG Acquires Infare and Receives New Investment from Vitruvian Partners
OAG, the world’s leading data platform for the global travel industry, has acquired Infare, the leading provider of competitor air travel data, from Ventiga Capital in a deal valuing the combined entity at over US$500m. Together, OAG and Infare have an exciting journey ahead to leverage a truly market-leading end-to-end data platform to serve mission-critical air travel intelligence needs across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230728627752/en/
With renowned industry heritage, both businesses share a deep passion for quality, accuracy, and customer-centricity. Together, there is a significant opportunity for OAG and Infare to better serve airline partners and the wider travel ecosystem with high-quality data and innovative solutions.
Infare is the partner of choice for airlines demanding the highest quality competitor air travel data source to support their growth. Combining OAG’s existing data solutions with airfare data creates a compelling proposition for customers who can get a broader picture of supply and demand. This enables customers to forecast resource, evaluate travel demand and competition, and build more complex and innovative models to drive revenue and profitable growth.
Through the acquisition, OAG now grows to over 300 employees globally across 10 offices.
Phil Callow, CEO of OAG, commented:
“The increasing dynamism in global travel and technology is fuelling a need for more sophisticated, granular data to understand, manage and unlock growth in air travel. The acquisition of Infare strengthens our ability to deliver consistent and accurate information across the wider supply and demand value chain. Together, we are enabling new and existing customers to thrive and innovate ahead of their counterparts. I am excited to welcome Infare colleagues to the OAG family.”
Nils Gelbjerg-Hansen, CEO of Infare, commented:
“Access to comprehensive and accurate data is paramount for making informed business decisions. Airlines rely on data to gain valuable insights into customer behaviour, market trends, and operational efficiency. Our technology platform, data sets, and intelligence software complement OAG’s and will greatly benefit our customers worldwide. We see this as a unique opportunity to expand our services and introduce new innovative products for our customers, we are excited about the journey ahead together.”
Both management teams will continue in the Group and will retain a shareholding, with fresh backing provided by Vitruvian Partners.
Ben Johnson, a Partner at Vitruvian, commented:
“OAG and Infare are both clear leaders in their respective global markets. The combination creates additional growth opportunities for both teams. Vitruvian is delighted to support this ambitious technology company and renew our relationship with them for the years to come.”
Niclas Gabrán, Managing Partner at Ventiga Capital Partners, commented:
“It has been a pleasure working together with Nils and his team to build Infare into a leading travel data provider through organic growth and acquisitions. Infare’s next chapter as a part of the OAG family will undoubtedly create further growth opportunities both within and outside the air travel sector.”
About OAG
OAG is the leading data platform for the global travel industry, powering the growth and innovation of the air travel ecosystem since 1929. It has the world’s largest network of flight information, covering the whole journey from planning to customer experience. Customers include airlines, airports, travel technology players, aviation service providers, government agencies, financial institutions, and consultancies. Headquartered in the UK, OAG has operations in the USA, Singapore, Japan, China, and Lithuania. For more information, visit: www.oag.com and follow us on Twitter @OAG Aviation.
About Infare
Infare is the leading competitor air travel data provider, empowering airlines to make effective pricing decisions. Infare’s mission is to fuel airline systems with high-quality competitor air travel data delivered daily, multiple times a day or live. Founded in 2000 and headquartered in Copenhagen, Denmark, the company has a global reach and presence worldwide. For more information, visit www.infare.com and follow us on LinkedIn.
About Vitruvian Partners
Vitruvian is an independent growth capital firm headquartered in London with a global presence. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning technology, financial services, healthcare, and business and consumer services. Vitruvian is among the largest pools of capital in Europe supporting innovative and higher growth companies. Vitruvian Funds have backed over 90 companies and have assets under management of €15+ billion. Notable investments to date include global market leaders and innovators in their field such as Skyscanner, Sykes Holiday Cottages, CFC Underwriting, CallCredit, Travel Counsellors, Trustpilot, Farfetch, Just Eat, Wise, and Global-e.
About Ventiga Capital Partners
Ventiga is an entrepreneurial and growth-focused investor partnering with exceptional entrepreneurs and management teams to achieve sustainable, profitable growth and transformational value through active, engaged, and responsible ownership. Ventiga invests in profitable growth companies with superior business expansion potential, primarily in the B2B services space.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728627752/en/
Contact information
Media Enquiries
pressoffice@oag.com
UK/EMEA /ASPAC
Dom Conolly/ Harvard PR
North America
Chrissy Azevedo
Corporate Ink for OAG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom